4-硝基吲哚-3-乙腈 | 4770-06-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 4-硝基吲哚-3-乙腈
• 英文名称: 4-nitro-3-indoleacetonitrile
• 英文别名: 4-nitroindole-3-acetonitrile；(4-nitro-indol-3-yl)-acetonitrile；(4-nitro-1H-indol-3-yl)acetonitrile；<4-Nitro-(indol-3-yl)>-acetonitril；4-Nitroindol-3-ylacetonitril；1H-Indole-3-acetonitrile, 4-nitro-；2-(4-nitro-1H-indol-3-yl)acetonitrile
• CAS: 4770-06-3
• 化学式: C₁₀H₇N₃O₂
• 分子量: 201.184
• InChiKey: ILCMRTYGNSGRBS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  85.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-硝基吲哚-3-乙腈 在 盐酸 、 sodium hydroxide 、 titanium(III) chloride 、 sodium hydride 、 copper(l) chloride 、 sodium nitrite 作用下， 以 四氢呋喃 、 甲醇 、 N,N-二甲基甲酰胺 、 苯 为溶剂， 反应 13.16h， 生成 4-氯吲哚-3-乙酸
  参考文献：
  名称：

  The chemistry of indoles. XXIV. Syntheses of 3-indoleacetic acid and 3-indoleacetonitrile having a halogeno group and a carbon functional group at the 4-position.

  摘要：

  首次合成了多种4-卤代-3-吲哚乙酸和-3-吲哚乙腈，采用了桑德梅耶反应或施密特反应，展示了4-吲哚二氮盐在4-取代吲哚化学中的多样性。通过区域选择性的铊化-卤化开发了一种实用的4-卤代吲哚合成方法，所生成的产品也可转化为4-卤代-3-吲哚乙酸。此外，还报道了4-甲酰基-3-吲哚乙腈的首次合成。

  DOI：

  10.1248/cpb.33.3696
• 作为产物：
  描述：

  4-硝基吲哚 以 水 、 溶剂黄146 、 N,N-二甲基甲酰胺 为溶剂， 反应 13.5h， 生成 4-硝基吲哚-3-乙腈
  参考文献：
  名称：

  The chemistry of indoles. XXIV. Syntheses of 3-indoleacetic acid and 3-indoleacetonitrile having a halogeno group and a carbon functional group at the 4-position.

  摘要：

  首次合成了多种4-卤代-3-吲哚乙酸和-3-吲哚乙腈，采用了桑德梅耶反应或施密特反应，展示了4-吲哚二氮盐在4-取代吲哚化学中的多样性。通过区域选择性的铊化-卤化开发了一种实用的4-卤代吲哚合成方法，所生成的产品也可转化为4-卤代-3-吲哚乙酸。此外，还报道了4-甲酰基-3-吲哚乙腈的首次合成。

  DOI：

  10.1248/cpb.33.3696

文献信息

• IMMUNOGENIC COMPOSITIONS FOR GRAM POSITIVE BACTERIA SUCH AS STREPTOCOCCUS AGALACTIAE
  申请人：Bell Ian M.

  公开号：US20090221535A1

  公开（公告）日：2009-09-03

  The present invention is directed to compounds of Formula I: I (where A 1 , A 2 , B 1 , B 2 , B 3 , B 4 , D 1 , D 2 , T, U, V, W, X, Y, Z. R 4 , R 5a ?, R 5b , R 5c , R 6 , m and n are defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

  本发明涉及式I的化合物：I（其中A1、A2、B1、B2、B3、B4、D1、D2、T、U、V、W、X、Y、Z、R4、R5a？、R5b、R5c、R6、m和n在此定义），用作CGRP受体的拮抗剂，用于治疗或预防CGRP参与的疾病，如头痛、偏头痛和群头痛。本发明还涉及包含这些化合物的制药组合物以及这些化合物和组合物在预防或治疗CGRP参与的这些疾病中的使用。
• Tricyclic Anilide Spirolactam Cgrp Receptor Antagonists
  申请人：Bell Ian M.

  公开号：US20080214511A1

  公开（公告）日：2008-09-04

  The present invention is directed to compounds of Formula I: I (where A 1 , A 2 , B 1 , B 2 , B 3 , B 4 , D 1 , D 2 , J, K, T, U, V, W, X, Y, Z, R 4 , R 5a , R 5b , R 5c , m and n are defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

  本发明涉及式I的化合物：I（其中A1，A2，B1，B2，B3，B4，D1，D2，J，K，T，U，V，W，X，Y，Z，R4，R5a，R5b，R5c，m和n在此定义），用作CGRP受体的拮抗剂，并用于治疗或预防CGRP参与的疾病，例如头痛、偏头痛和群集性头痛。本发明还涉及包含这些化合物的制药组合物以及在预防或治疗CGRP参与的这些疾病中使用这些化合物和组合物的用途。
• Spirolactam Tricyclic CGRP Receptor Antagonists
  申请人：Bell Ian M.

  公开号：US20090105219A1

  公开（公告）日：2009-04-23

  Compounds of formula I: (wherein variables A 1 , A 2 , A 3 , A 4 , A 5 , A 6 , A 7 , B 1 , B 2 , B 3 , B 4 , D 1 , D 2 , E 1 , E 2 , E 3 , E 4 , E 5 , G 1 , G 2 , J, K, T, U, V, W, X, Y and Z are as described herein) which are antagonists of CGRP receptors and which are useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

  化合物I的公式为：（其中变量A1，A2，A3，A4，A5，A6，A7，B1，B2，B3，B4，D1，D2，E1，E2，E3，E4，E5，G1，G2，J，K，T，U，V，W，X，Y和Z如本文所述），这些化合物是CGRP受体拮抗剂，可用于治疗或预防CGRP参与的疾病，如偏头痛。本发明还涉及含有这些化合物的药物组合物以及这些化合物和组合物在预防或治疗CGRP参与的疾病方面的使用。
• Spirohydantoin Tricyclic CGRP Receptor Antagonists
  申请人：Bell Ian M.

  公开号：US20090281080A1

  公开（公告）日：2009-11-12

  Compounds of formula I: (wherein variables A 1 , A 2 , A 3 , A 4 , A 5 , A 6 , A 7 , B 1 , B 2 , B 3 , B 4 , D 1 , D 2 , E 1 , E 2 , E 3 , E 4 , E 5 , G 1 , G 2 , R 6 , T, U, V, W, X, Y and Z are as described herein) which are antagonists of CGRP receptors and which are useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

  公式I的化合物：（其中变量A1，A2，A3，A4，A5，A6，A7，B1，B2，B3，B4，D1，D2，E1，E2，E3，E4，E5，G1，G2，R6，T，U，V，W，X，Y和Z如本文所述），这些化合物是CGRP受体的拮抗剂，对于治疗或预防CGRP参与的疾病，如偏头痛，具有用途。本发明还涉及包含这些化合物的制药组合物以及在预防或治疗CGRP参与的这些疾病中使用这些化合物和组合物的用途。
• Spirolactam tricyclic CGRP receptor antagonists
  申请人：Merck Sharp & Dohme Corp.

  公开号：US07947677B2

  公开（公告）日：2011-05-24

  Compounds of formula I: (wherein variables A1, A2, A3, A4, A5, A6, A7, B1, B2, B3, B4, D1, D2, E1, E2, E3, E4, E5, G1, G2, J, K, T, U, V, W, X, Y and Z are as described herein) which are antagonists of CGRP receptors and which are useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

  公式I的化合物：（其中变量A1，A2，A3，A4，A5，A6，A7，B1，B2，B3，B4，D1，D2，E1，E2，E3，E4，E5，G1，G2，J，K，T，U，V，W，X，Y和Z如上所述），它们是CGRP受体的拮抗剂，并且在治疗或预防CGRP参与的疾病，例如偏头痛方面非常有用。本发明还涉及包含这些化合物的药物组合物以及在预防或治疗CGRP参与的这些疾病方面使用这些化合物和组合物。